|
CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
|
AU3249897A
(en)
*
|
1996-07-01 |
1998-01-21 |
Jim A. Wright |
Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
|
|
US6593305B1
(en)
|
1996-08-02 |
2003-07-15 |
Genesense Technologies Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
JP2002501486A
(ja)
|
1997-03-19 |
2002-01-15 |
ジェネセンス・テクノロジーズ・インコーポレーテッド |
リボヌクレオチドレダクターゼｒ１を利用した悪性腫瘍の抑制
|
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
|
US6610539B1
(en)
*
|
1997-07-10 |
2003-08-26 |
Genesense Technologies, Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
EP1584681A3
(en)
*
|
1997-07-10 |
2005-11-09 |
GeneSense Technologies Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AUPP249298A0
(en)
*
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
KR20010042069A
(ko)
*
|
1998-03-20 |
2001-05-25 |
베니텍 오스트레일리아 리미티드 |
유전자 발현 조절방법
|
|
EP2314700A1
(en)
*
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
|
US6121000A
(en)
*
|
1999-02-11 |
2000-09-19 |
Genesense Technologies, Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
|
US6642033B1
(en)
*
|
1999-07-20 |
2003-11-04 |
V.I. Technologies, Inc. |
Nucleic acids for detecting parvovirus and methods of using same
|
|
US6423885B1
(en)
*
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
|
CN1301816A
(zh)
*
|
1999-12-27 |
2001-07-04 |
上海博德基因开发有限公司 |
一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
|
|
CA2403162A1
(en)
*
|
2000-03-17 |
2001-09-27 |
Benitec Australia Ltd. |
Genetic silencing
|
|
US20020132257A1
(en)
*
|
2001-01-31 |
2002-09-19 |
Tony Giordano |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
|
DE10131148A1
(de)
*
|
2001-06-28 |
2003-01-16 |
I P L Internat Pharmaceutics L |
Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
|
|
EP1597365B1
(en)
*
|
2003-02-10 |
2013-10-09 |
Lorus Therapeutics Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
US20070274947A1
(en)
*
|
2003-05-21 |
2007-11-29 |
Young Aiping H |
Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer
|
|
WO2004106518A1
(en)
*
|
2003-05-31 |
2004-12-09 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
|
WO2005040428A2
(en)
|
2003-10-23 |
2005-05-06 |
Illumigen Biosciences, Inc. |
Detection of mutations in a gene associated with resistance to viral infection, oas1
|
|
JP2007520474A
(ja)
*
|
2004-01-12 |
2007-07-26 |
ジーンセンス テクノロジーズ インコーポレーテッド |
リボヌクレオチドレダクターゼｒ２に向けられたアンチセンスオリゴヌクレオチドおよび癌の処置のための併用療法におけるこの使用
|
|
WO2005115405A1
(en)
*
|
2004-04-28 |
2005-12-08 |
Molecules For Health, Inc. |
Methods for treating or preventing restenosis and other vascular proliferative disorders
|
|
EP2322650A1
(en)
*
|
2004-05-14 |
2011-05-18 |
Rosetta Genomics Ltd |
MicroRNAs and uses thereof
|
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
|
CA2577036A1
(en)
*
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
US20060185027A1
(en)
*
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
|
JP2008537551A
(ja)
*
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ， インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
|
EP2030615A3
(en)
*
|
2007-08-13 |
2009-12-02 |
ELFORD, Howard L. |
Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
|
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
BRPI0820722A2
(pt)
|
2007-12-20 |
2015-06-16 |
Novartis Ag |
Derivados de tiazol usados como inibidores de pi 3 cinases
|
|
WO2010027279A2
(en)
*
|
2008-09-04 |
2010-03-11 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
|
WO2010054221A2
(en)
|
2008-11-06 |
2010-05-14 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
EP2851426B1
(en)
*
|
2010-10-18 |
2018-08-22 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of RRM2 genes
|
|
MX343706B
(es)
|
2011-01-31 |
2016-11-18 |
Novartis Ag |
Derivados heterocíclicos novedosos.
|
|
BR112014009890A2
(pt)
|
2011-10-28 |
2020-10-27 |
Novartis Ag |
derivados de purina e seu uso no tratamento de doença
|
|
BR112014028420A2
(pt)
|
2012-05-16 |
2017-09-19 |
Novartis Ag |
regime de dosagem para um inibidor de quinase pi-3
|
|
PL3076969T3
(pl)
|
2013-12-06 |
2022-01-17 |
Novartis Ag |
Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
|
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|